Investor Presentaiton

SELECT TRIALS - EARLY PHASE NEURODEGENERATION Lilly Molecule Study Indication* Title Phase Patients O-GlcNAcase Inh. NCT05063539 Alzheimer Disease A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease 2 330 SARM1 CNS Inhibitor NCT05492201 Healthy A Study of LY3873862 in Healthy Participants 1 90 GRN Gene Therapy NCT04408625 Frontotemporal Dementia Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM) 1|2 15 GBA1 Gene Therapy NCT04411654 GBA1 Gene Therapy NCT04127578 Gaucher Disease, Type 2 Parkinson Disease Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) 1|2 15 Primary Outcome** Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuation Primary Completion Completion Jul 2024 Aug 2024 Apr 2024 Apr 2024 Dec 2027 Dec 2027 Sep 2028 Sep 2028 Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One 12 GBA1 Mutation (PROPEL) 20 Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Jun 2029 Jun 2029 GBA1 Gene Therapy NCT05487599 Gaucher Disease A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) 1|2 15 Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events Sep 2030 Sep 2030 (SAEs) * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use 2023 Q2 EARNINGS Source: clinicaltrials.gov, July 13, 2023 55

View entire presentation